Corbus Offers Update of Scleroderma Therapy Anabasum at Ongoing ACR Meeting

Scleroderma News—November 6, 2017

Scleroderma News reported on a recent study co-authored by HSS rheumatologist Robert F. Spiera, MD, stating that a cannabinoid-derived drug could resolve skin inflammation in those with diffuse cutaneous scleroderma.

The study was presented at the American College of Rheumatology (ACR) Annual Meeting, and showed that the treatment normalized activity in genes related to inflammation.